Role of proinflammatory cytokines in the pathophysiology of osteoarthritis

Osteoarthritis (OA) is associated with cartilage destruction, subchondral bone remodeling and inflammation of the synovial membrane, although the etiology and pathogenesis underlying this debilitating disease are poorly understood. Secreted inflammatory molecules, such as proinflammatory cytokines, are among the critical mediators of the disturbed processes implicated in OA pathophysiology. Interleukin (IL)-1β and tumor necrosis factor (TNF), in particular, control the degeneration of articular cartilage matrix, which makes them prime targets for therapeutic strategies. Animal studies provide support for this approach, although only a few clinical studies have investigated the efficacy of blocking these proinflammatory cytokines in the treatment of OA. Apart from IL-1β and TNF, several other cytokines including IL-6, IL-15, IL-17, IL-18, IL-21, leukemia inhibitory factor and IL-8 (a chemokine) have also been shown to be implicated in OA and could possibly be targeted therapeutically. This Review discusses the current knowledge regarding the role of proinflammatory cytokines in the pathophysiology of OA and addresses the potential of anticytokine therapy in the treatment of this disease.

[1]  W. B. van den Berg,et al.  Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice. , 1997, The American journal of pathology.

[2]  J. Pelletier,et al.  Differential effects of IL-8, LIF (pro-inflammatory) and IL-11 (anti-inflammatory) on TNF-alpha-induced PGE(2)release and on signalling pathways in human OA synovial fibroblasts. , 1999, Cytokine.

[3]  C. Brinckerhoff,et al.  Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. , 2000, Arthritis and rheumatism.

[4]  F. Mallein-Gerin,et al.  Interleukin-6 (IL-6) and/or Soluble IL-6 Receptor Down-regulation of Human Type II Collagen Gene Expression in Articular Chondrocytes Requires a Decrease of Sp1·Sp3 Ratio and of the Binding Activity of Both Factors to the COL2A1 Promoter* , 2008, Journal of Biological Chemistry.

[5]  Xiao-Yu Song,et al.  Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor alpha in immature bovine and adult human articular cartilage. , 2009, Arthritis and rheumatism.

[6]  W. Koopman.  Arthritis and allied conditions;: A textbook of rheumatology , 1972 .

[7]  M. Goldring,et al.  NF-kappaB signaling: multiple angles to target OA. , 2010, Current drug targets.

[8]  M. Genovese,et al.  Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. , 2008, Arthritis and rheumatism.

[9]  H. Ma,et al.  Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis , 2005, Nature.

[10]  M. Meseck,et al.  Functional Genomic Analysis of Type II IL-1β Decoy Receptor: Potential for Gene Therapy in Human Arthritis and Inflammation1 , 2002, The Journal of Immunology.

[11]  A. Mobasheri,et al.  Curcumin protects human chondrocytes from IL-l1beta-induced inhibition of collagen type II and beta1-integrin expression and activation of caspase-3: an immunomorphological study. , 2005, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[12]  M. Enomoto-Iwamoto,et al.  Wnt/β-catenin signaling stimulates matrix catabolic genes and activity in articular chondrocytes: its possible role in joint degeneration , 2008, Laboratory Investigation.

[13]  W. B. van den Berg,et al.  Male IL-6 gene knock out mice developed more advanced osteoarthritis upon aging. , 2005, Osteoarthritis and cartilage.

[14]  M. Hochberg,et al.  Reliability of a quantification imaging system using magnetic resonance images to measure cartilage thickness and volume in human normal and osteoarthritic knees. , 2003, Osteoarthritis and cartilage.

[15]  A. Levine,et al.  The role of the interleukin-6/gp130 signaling pathway in bone metabolism. , 2006, Vitamins and hormones.

[16]  H. Schulze-Koops,et al.  Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade , 2006, Annals of the rheumatic diseases.

[17]  R. Zernicke,et al.  Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[18]  H. Scharf,et al.  Interleukin-1β Induces Different Gene Expression of Stromelysin, Aggrecan and Tumor-Necrosis-Factor-Stimulated Gene 6 in Human Osteoarthritic Chondrocytes in vitro , 2000, Pathobiology.

[19]  J. Pelletier,et al.  Interleukin 17 (IL-17) induces collagenase-3 production in human osteoarthritic chondrocytes via AP-1 dependent activation: differential activation of AP-1 members by IL-17 and IL-1beta. , 2002, The Journal of rheumatology.

[20]  B. Henderson,et al.  Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. , 1989, Clinical and experimental immunology.

[21]  J F Beary,et al.  Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period , 2007, Annals of the rheumatic diseases.

[22]  V. Lefebvre,et al.  Modulation by interleukin 1 and tumor necrosis factor alpha of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. , 1990, Biochimica et biophysica acta.

[23]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[24]  J. Pelletier,et al.  Osteoarthritic synovial fibroblasts possess an increased level of tumor necrosis factor-receptor 55 (TNF-R55) that mediates biological activation by TNF-alpha. , 1997, The Journal of rheumatology.

[25]  A. Lomri,et al.  Reactive oxygen species and superoxide dismutases: role in joint diseases. , 2007, Joint, bone, spine : revue du rhumatisme.

[26]  H. Tilg,et al.  IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. , 1997, Immunology today.

[27]  C. Jorgensen,et al.  Erosive osteoarthritis of the hand: clinical experience with anakinra , 2009, Annals of the rheumatic diseases.

[28]  C. McIlwraith,et al.  Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene , 2002, Gene Therapy.

[29]  N. Lee,et al.  Shear-induced Interleukin-6 Synthesis in Chondrocytes , 2010, The Journal of Biological Chemistry.

[30]  J. Dingle,et al.  In vivo studies of cartilage regeneration after damage induced by catabolin/interleukin-1. , 1991, Annals of the rheumatic diseases.

[31]  W. B. van den Berg,et al.  Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: prominent role of Wnt-induced signaling protein 1. , 2009, Arthritis and rheumatism.

[32]  R. Mason,et al.  Gene deletion of either interleukin-1beta, interleukin-1beta-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. , 2003, Arthritis and rheumatism.

[33]  R. Zernicke,et al.  In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat. , 2010, Arthritis and rheumatism.

[34]  J. Pelletier,et al.  In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. , 1997, Arthritis and rheumatism.

[35]  J. Smolen,et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.

[36]  D. Zukor,et al.  Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. , 2005, Arthritis and rheumatism.

[37]  R. D. Dyer,et al.  Discovery and Characterization of a Novel Inhibitor of Matrix Metalloprotease-13 That Reduces Cartilage Damage in Vivo without Joint Fibroplasia Side Effects* , 2007, Journal of Biological Chemistry.

[38]  D. Loeuille,et al.  Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. , 2009, Arthritis and rheumatism.

[39]  C. Christiansen,et al.  Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. , 2008, Osteoarthritis and cartilage.

[40]  K. Konstantopoulos,et al.  Prostaglandin E2 induces interleukin-6 expression in human chondrocytes via cAMP/protein kinase A- and phosphatidylinositol 3-kinase-dependent NF-kappaB activation. , 2010, American journal of physiology. Cell physiology.

[41]  J. Saklatvala.  Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage , 1986, Nature.

[42]  T. Sculco,et al.  Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. , 2007, Osteoarthritis and cartilage.

[43]  T. Spector,et al.  Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford study , 2009, Arthritis and rheumatism.

[44]  J. Heath,et al.  Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. , 2001, Arthritis and rheumatism.

[45]  B. Giraudeau,et al.  Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. , 2005, The Journal of rheumatology.

[46]  Xin Fu,et al.  Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. , 2008, Osteoarthritis and cartilage.

[47]  J. Pelletier,et al.  Mitogen‐activated protein kinase and nuclear factor κB together regulate interleukin‐17–induced nitric oxide production in human osteoarthritic chondrocytes: Possible role of transactivating factor mitogen–activated protein kinase–activated protein kinase (MAPKAPK) , 1999 .

[48]  J. Pelletier,et al.  The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. , 2007, Arthritis and rheumatism.

[49]  R. Barve,et al.  A review of the ADAMTS family, pharmaceutical targets of the future. , 2009, Current pharmaceutical design.

[50]  B. Wilbrink,et al.  The effect of human interleukin 1 on proteoglycan metabolism in human and porcine cartilage explants. , 1990, The Journal of rheumatology.

[51]  U. Gatzemeler.  Recombinant G-CSF with combination chemotherapy in small cell lung cancer: Results of a double blind, placebo controlled, randomised trial , 1991 .

[52]  T. Spector,et al.  Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. , 2006, Arthritis and rheumatism.

[53]  S. Kwan Tat,et al.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004, Cytokine & growth factor reviews.

[54]  V. Turk,et al.  Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis , 2010, Biological chemistry.

[55]  A. Steensberg,et al.  IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. , 2003, American journal of physiology. Endocrinology and metabolism.

[56]  M. Nagashima,et al.  Characterization of infiltrating T cells and Th1/Th2-type cytokines in the synovium of patients with osteoarthritis. , 2002, Osteoarthritis and cartilage.

[57]  H. Ma,et al.  Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. , 2004, Arthritis and rheumatism.

[58]  J. Marshall,et al.  Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  P. Heinrich,et al.  Interleukin‐1β induces synthesis and secretion of interleukin‐6 in human chondrocytes , 1990, FEBS letters.

[60]  Wei Li,et al.  Human Hip Joint Cartilage: MRI Quantitative Thickness and Volume Measurements Discriminating Acetabulum and Femoral Head , 2008, IEEE Transactions on Biomedical Engineering.

[61]  A. Jeng,et al.  The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. , 2004, Current medicinal chemistry.

[62]  W. Arend.  Interleukin-1 receptor antagonist. , 1993, Advances in immunology.

[63]  G. Burmester,et al.  Cellular immune response toward human articular chondrocytes. T cell reactivities against chondrocyte and fibroblast membranes in destructive joint diseases. , 1990, Arthritis and rheumatism.

[64]  Kwan Tat Steeve,et al.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004 .

[65]  J. Raynauld,et al.  Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis , 2010, Annals of the rheumatic diseases.

[66]  A. Mobasheri,et al.  Targeting matrix metalloproteinases in inflammatory conditions. , 2009, Current drug targets.

[67]  M. Genovese,et al.  A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. , 2007, The Journal of rheumatology.

[68]  E Vignon,et al.  Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI , 2008, Annals of the rheumatic diseases.

[69]  J. Raynauld,et al.  A new non-invasive method to assess synovitis severity in relation to symptoms and cartilage volume loss in knee osteoarthritis patients using MRI. , 2008, Osteoarthritis and cartilage.

[70]  R. Terkeltaub,et al.  Monocyte chemoattractant protein-1 (MCP-1) expression in human articular cartilage. Induction by peptide regulatory factors and differential effects of dexamethasone and retinoic acid. , 1992, The Journal of clinical investigation.

[71]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[72]  J. Pelletier,et al.  Interleukin 17, a nitric oxide-producing cytokine with a peroxynitrite-independent inhibitory effect on proteoglycan synthesis. , 2002, The Journal of rheumatology.

[73]  P. Dieppe,et al.  Tumor necrosis factor-alpha receptor expression on chondrocytes isolated from human articular cartilage. , 1994, The Journal of rheumatology.

[74]  T. Spector,et al.  Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study , 2007, Arthritis research & therapy.

[75]  M. Nevitt,et al.  Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women. , 2007, Arthritis and rheumatism.

[76]  G. Stein,et al.  Increased mRNA expression and protein secretion of interleukin‐6 in primary human osteoblasts differentiated in vitro from rheumatoid and osteoarthritic bone , 2001, Journal of cellular biochemistry.

[77]  S. Jimenez,et al.  NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis , 2006 .

[78]  J. Pelletier,et al.  The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. , 2008, Clinical and experimental rheumatology.

[79]  A. Fioravanti,et al.  Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study , 2009, Rheumatology International.

[80]  A. Mantovani,et al.  The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. , 1994, Immunology today.

[81]  J. Smolen,et al.  Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlle , 2010, Arthritis and rheumatism.

[82]  R. Terkeltaub,et al.  Cartilage and joint inflammation. Regulation of IL-8 expression by human articular chondrocytes. , 1992, Journal of immunology.

[83]  K. Fukuo,et al.  Transcriptional suppression by interleukin‐1 and interferon‐γ of type II collagen gene expression in human chondrocytes , 1994 .

[84]  Claude Kauffmann,et al.  Computer-aided method for quantification of cartilage thickness and volume changes using MRI: validation study using a synthetic model , 2003, IEEE Transactions on Biomedical Engineering.

[85]  T. Kirkwood,et al.  Superoxide dismutase downregulation in osteoarthritis progression and end-stage disease , 2010, Annals of the rheumatic diseases.

[86]  J. Pelletier,et al.  PPARgamma ligands as modulators of inflammatory and catabolic responses in arthritis. An overview. , 2002, The Journal of rheumatology.

[87]  J. Pelletier,et al.  Mitogen-activated protein kinase and nuclear factor kappaB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen-activated protein kinase-activated proten kinase (MAPKAPK). , 1999, Arthritis and rheumatism.

[88]  D A Bloch,et al.  Meniscal tear and extrusion are strongly associated with progression of symptomatic knee osteoarthritis as assessed by quantitative magnetic resonance imaging , 2004, Annals of the rheumatic diseases.

[89]  S. Kaneko,et al.  Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. , 2000, Cytokines, cellular & molecular therapy.

[90]  P. Heinrich,et al.  Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level , 1993, Molecular and cellular biology.

[91]  L. Joosten,et al.  Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. , 2000, Arthritis and rheumatism.

[92]  J. Pelletier,et al.  Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. , 1996, Arthritis and rheumatism.

[93]  P. Guerne,et al.  IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro. , 1990, Journal of immunology.

[94]  M. Lotz,et al.  Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. , 2001, Arthritis and rheumatism.

[95]  Bernard I. Comron,et al.  Arthritis and Allied Conditions , 1940, The Indian Medical Gazette.

[96]  Gillian Murphy,et al.  Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? , 2008, Nature Clinical Practice Rheumatology.

[97]  J. Bondeson,et al.  The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis , 2006, Arthritis research & therapy.

[98]  M. Lagerquist,et al.  Long‐term anti‐arthritic and anti‐osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis , 2008, Clinical and experimental immunology.

[99]  J. Raynauld,et al.  Fully automated system for the quantification of human osteoarthritic knee joint effusion volume using magnetic resonance imaging , 2010, Arthritis research & therapy.

[100]  Chafik Ghayor,et al.  Sp1 and Sp3 Transcription Factors Mediate Interleukin-1β Down-regulation of Human Type II Collagen Gene Expression in Articular Chondrocytes* , 2003, Journal of Biological Chemistry.

[101]  J. Pelletier,et al.  The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. , 1996, The Journal of clinical investigation.

[102]  H. Potter,et al.  Local cytokine profiles in knee osteoarthritis: elevated synovial fluid interleukin-15 differentiates early from end-stage disease. , 2009, Osteoarthritis and cartilage.

[103]  K. Schwarz.  The Chingford Study. , 1981, Public health.

[104]  Y. Henrotin,et al.  Interleukin-1beta and interleukin-6 disturb the antioxidant enzyme system in bovine chondrocytes: a possible explanation for oxidative stress generation. , 2008, Osteoarthritis and cartilage.

[105]  J. Magdalou,et al.  Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. , 2001, Arthritis and rheumatism.

[106]  M. Dougados,et al.  Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis -- results of a 1 year longitudinal arthroscopic study in 422 patients. , 2005, Osteoarthritis and cartilage.

[107]  B. Dewald,et al.  Production of interleukin-1 receptor antagonist, inflammatory chemotactic proteins, and prostaglandin E by rheumatoid and osteoarthritic synoviocytes--regulation by IFN-gamma and IL-4. , 1994, Journal of Immunology.

[108]  M. Tortorella,et al.  The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. , 2001, Osteoarthritis and cartilage.

[109]  G. Kollias,et al.  Interleukin 6 Is Required for the Development of Collagen-induced Arthritis , 1998, The Journal of experimental medicine.

[110]  M. Mawatari,et al.  Serum concentrations of interleukin-6 in patients following unilateral versus bilateral total knee arthroplasty , 2009, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[111]  J. Pelletier,et al.  The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. , 1992, Arthritis and rheumatism.

[112]  J. Martel-Pelletier,et al.  Can altered production of interleukin-1beta, interleukin-6, transforming growth factor-beta and prostaglandin E(2) by isolated human subchondral osteoblasts identify two subgroups of osteoarthritic patients. , 2002, Osteoarthritis and cartilage.

[113]  P. Baeuerle,et al.  Expression of the types A and B tumor necrosis factor (TNF) receptors is independently regulated, and both receptors mediate activation of the transcription factor NF-kappa B. TNF alpha is not needed for induction of a biological effect via TNF receptors. , 1990, The Journal of biological chemistry.

[114]  M. Goldring,et al.  The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. , 1998, Arthritis and rheumatism.

[115]  M. Wolzt,et al.  C‐reactive protein is expressed and secreted by peripheral blood mononuclear cells , 2006, Clinical and experimental immunology.

[116]  C. Séguin,et al.  TNFα suppresses link protein and type II collagen expression in chondrocytes: Role of MEK1/2 and NF‐κB signaling pathways , 2003 .

[117]  Ronenn Roubenoff,et al.  Arthritis and Allied Conditions: A Textbook of Rheumatology , 1993 .

[118]  B. Naume,et al.  Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. , 1991, Journal of immunology.

[119]  Xiaoling Zhang,et al.  Suppression of early experimental osteoarthritis by gene transfer of interleukin‐1 receptor antagonist and interleukin‐10 , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[120]  M. Lotz,et al.  IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. , 1999, Journal of immunology.

[121]  David T Felson,et al.  Clinical practice. Osteoarthritis of the knee. , 2006, The New England journal of medicine.

[122]  A. Facchini,et al.  Contribution of interleukin 17 to human cartilage degradation and synovial inflammation in osteoarthritis. , 2002, Osteoarthritis and cartilage.

[123]  J. Pelletier,et al.  Human synovial fibroblasts coexpress IL-1 receptor type I and type II mRNA. The increased level of the IL-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[124]  M. Sheppard,et al.  In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. , 1999, The American journal of pathology.

[125]  C. Gabay,et al.  Production of interleukin-1 receptor antagonist by human articular chondrocytes , 2002, Arthritis Research & Therapy.

[126]  J. Pelletier,et al.  Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. , 2005, Arthritis and rheumatism.